Abstract
Well-differentiated astrocytomas may transform into malignant astrocytomas in time. In surgical specimens, when the histological picture strictly corresponds to that of grade II glioma, the transformation is unpredictable. Clinically, the bad outcome of a quota of astrocytomas is a well known phenomenon. The use of proliferation markers, and recently of MIB-1 LI, for detecting the proliferation potential comes out to be a useful tool for prognosis. A survival analysis of fifty astrocytomas grade II according to the WHO classification was performed with univariate and multivariate analysis of a series of clinical and histological parameters. MIB-1 LI was calculated and compared with all the other parameters. A cut-off of 8% of MIB-1 LI divided the astrocytomas in two groups with significantly different survival (p=0.0066): median survival time of 1062 versus 1686 days. According to multivariate analysis MIB-1 LI resulted to be an independent factor (p=0.002) along with extension of surgical removal (partial versus total), postoperative Karnofsky status (≥ 70 versus < 70) and age (≤ 30 versus > 30). The interpretation of well-differentiated astrocytomas with high MIB-1 LI is that the increasing number of cycling cells precedes phenotypic transformation. MIB-1 LI can be used as a prognostic factor.
Similar content being viewed by others
References
Kleihues P, Burger PC, Scheithauer BW: Histological typing of tumours of the central nervous system. In: World Health Organization International Histological Classification of Tumours. Springer-Verlag, Berlin 13–16, 1993
Kernohan JW, Mabon RF, Svien HJ, Adson AW: A simplified classification of gliomas. Proc Staff Meet Mayo Clin 24: 71–75, 1949
Ringertz N: Grading of gliomas. Acta Pathol Microbiol Scand 27: 51–64, 1950
Nelson DF, Nelson JF, Davis DR et al.: Survival and prognosis of patients with astrocytoma with atypical on anaplastic features. J Neuro-Oncol 3: 99–103, 1985
Burger PC, Scheithauer BW, Vogel FS: Surgical Pathology of the Nervous System and its Coverings. 3rd edition, Churchill Livingston, New York 193–234, 1991
Daumas-Duport C, Scheithauer B, O'Fallon J, Kelly P: Grading of astrocytomas. Cancer 62: 2152–2165, 1988
Burger P: Revising the World Health Organization (WHO) Blue Book - Histological typing of tumours of the central nervous system. J Neuro-Oncol 24: 3–7, 1995
Raghavan R, Steart PV, Weller RO: Cell proliferation patterns in the diagnosis of astrocytomas, anaplastic astrocytomas and glioblastoma multiforme: a Ki-67 study. Neuropathol Appl Neurobiol 16: 123–133, 1990
Schiffer D, Chiò A, Giordana MT, Pezzulo T, Vigliani MC: Proliferating cell nuclear antigen expression in brain tumors, and its prognostic role in ependymomas: an immunohistochemical study. Acta Neuropathol 85: 495–502, 1993
Sallinen PK, Haapasalo HK, Visakorpi T, Helén PT, Rantala IS, Isola JJ, Helin HJ: Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174: 275–282, 1994
Schiffer D, Cavalla P, Giordana MT, Chiò A, Dutto A: Heterogeneity and cell loss in assessment of proliferation potential of brain tumors (abs). J Neuropathol Exp Neurol 54: 420, 1995
Cattoretti G, Becker MHG, Key G, Dochrow M, Sclüter C, Galle J, Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357–363, 1992
Gerdes J: Immunohistochemical assessment of cell proliferation (abs). Brain Pathol 4: 298, 1994
Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observation of each patient: analysis and examples. Br J Cancer 35: 1–39, 1977
Cox DR: Regression models and life tables. J R Stat Soc (B) 34: 187–202, 1972
SAS Institute Inc.: SAS/STAT Software, release 6.10. Cary, NC: SAS Institute Inc, 1994
Dixon WJ (ed): BMDP. Statistical Software Manual: Release 7.0. Berkely, CA University of California Press, 1992
Schiffer D: Brain tumors. Pathology and its Biological Correlates. Springer-Verlag, Berlin 112–165, 1993
Morantz RA: Low grade astrocytomas. In: Kaye AH, Lawy ER Jr (eds) Brain Tumors. Churchill Livingstone, Edinburgh 433–448, 1995
Shaw EG, Daumas-Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, Laws ER, Okazaki H: Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70: 853–861, 1989
McCormack BM, Miller DC, Budzilovich GN, Voorhees GJ, Ransohof FFJ: Treatment and survival of low-grade astrocytomas in adults, 1977- 1988. Neurosurgery 31: 636–642, 1992
Laws ER Jr, Taylor WF, Clifton MB, Okazaki H: Neurosurgical management of low-grade astrocytoma of the cerebral hemispheres. J Neurosurg 61: 665–673, 1984
Soffietti R, Chiò A, Giordana MT, Vasario E, Schiffer D: Prognostic factors in well-differentiated cerebral astrocytomas in the adult. Neurosurgery 24: 686–692, 1989
Vertosick FT, Selker RG, Arena VC: Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28: 496–501, 1991
Coons SW, Johnson PC: Regional heterogeneity in the DNA content of human gliomas. Cancer 72: 3052–3060, 1993
Russel DS, Rubinstein LJ: Pathology of Tumors of the Nervous System. Williams & Wilkins, Baltimore, 1989
Linden MC, Torres FX, Kubus J, Zarbo RJ: Clinical application of morphologic and immunohistochemical assessment of cell proliferation. Am J Clin Pathol 97: 1–12S, 1995
Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T: Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB-1 monoclonal antibody on archival material. Acta Neuropathol 87: 47–54, 1994
Onda K, Davis RL, Shibuya M, Wilson CB, Hoshino T: Correlation between the bromodeoxyuridine labeling index and the MIB-1 and Ki-67 proliferating cell indices in cerebral gliomas. Cancer 74: 1921–1926, 1994
Hoyt JH, Gown AM, Kim DK, Berger MS: Analysis of proliferative grade in glial neoplasms using antibodies to the Ki-67 defined antigen and PCNA in formalin fixed, deparaffinized tissues. J Neuro-Oncol 24: 163–169, 1995
Hoshino T, Rodriguez LA, Cho KG, Lee KS, Wilson CB, Edwards MSB, Levin VA, Davis RL: Prognostic implications of the proliferative potential of low-grade astrocytomas. J Neurosurg 69: 839–842, 1988
Ito S, Chandler KL, Prados MD, Lamborn K, Wynnie J, Malec MK, Wilson CV, Davis RL, Hoshino T: Proliferative potential and prognostic evaluation of low-grade astrocytomas. J Neuro-Oncol 19: 1–9, 1994
Davis RL, Onda K, Shubuka M, Lamborn K, Hoshino T: Proliferation markers in gliomas: a comparison of BUdR, Ki-67, and MIB-1. J Neuro-Oncol 24: 9–12, 1995
Vigliani MC, Chiò A, Pezzulo T, Soffietti R, Giordana MT, Schiffer D: Proliferating cell nuclear antigen (PCNA) in low-grade astrocytomas: its prognostic significance. Tumori 80: 295–300, 1994
Weir B, Grace M: The relative significance of factors affecting postoperative survival in astrocytomas, grades one and two. Can J Neurol Sci 3: 47–50, 1976
North CA, North RB, Epstein JA, Piantadosi S, Wharam MD: Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy. Cancer 66: 6–14, 1990
Cohadon F, Aouad N, Rougier A, Vital C, Rivel J, Dartigues JF: Histologic and non-histologic factors correlated with survival time in supratentorial astrocytic tumors. J Neuro-Oncol 3: 105–111, 1985
Piepmeier JM: Observations on the current treatment of low-grade astrocytic tumors of the cerebral hemispheres. J Neurosurg 67: 177–181, 1987
Boyages J, Tiver KW: Cerebral hemisphere astrocytoma. Treatment results. Radiother Oncol 8: 209–216, 1987
Medbery CA III, Straus KL, Steinberg SM, Cotelingam JD, Fisher WS: Low-grade astrocytomas. Treatment results and prognostic variables. Int J Radiat Oncol Biol Phys 15: 837–841, 1987
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schiffer, D., Cavalla, P., Chiò, A. et al. Proliferative activity and prognosis of low-grade astrocytomas. J Neurooncol 34, 31–35 (1997). https://doi.org/10.1023/A:1005755119526
Issue Date:
DOI: https://doi.org/10.1023/A:1005755119526